Finerenone in Heart Failure—A Novel Therapeutic Approach
Author Information
Author(s): Holst-Hansen Amalie, Grimm Daniela, Wehland Markus
Primary Institution: Aarhus University
Hypothesis
The review aims to describe the new drug finerenone and its effects on heart failure.
Conclusion
Finerenone shows promise in reducing cardiovascular outcomes in heart failure patients, particularly those with chronic kidney disease and type 2 diabetes.
Supporting Evidence
- Finerenone has shown a reduction in cardiovascular outcomes among patients with chronic kidney disease and type 2 diabetes.
- The drug has a high selectivity for mineralocorticoid receptors, leading to fewer side effects compared to other treatments.
- Clinical trials indicate that finerenone can reduce hospitalization rates for heart failure.
Takeaway
Finerenone is a new medicine that helps people with heart failure feel better by reducing inflammation and fibrosis in the heart.
Methodology
This review discusses clinical studies and trials related to finerenone's effects on heart failure.
Potential Biases
Potential bias due to funding sources and the need for independent studies.
Limitations
The studies reviewed were funded by Bayer, which may introduce bias.
Participant Demographics
Participants included those with heart failure, chronic kidney disease, and type 2 diabetes.
Statistical Information
P-Value
p = 0.03
Confidence Interval
95% CI of 0.76 to 0.98
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website